Nicox Announces Research Collaboration on Novel Ophthalmic

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Jun 6, 2018 at 1:45 AM 661

Nicox Announces Research Collaboration on Novel Ophthalmic Therapeutics with Ironwood Pharmaceuticals

Press Release

Nicox Announces Research Collaboration on Novel Ophthalmic Therapeutics with Ironwood Pharmaceuticals

................................................ June 6, 2018 - release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced its entry into a research collaboration with Ironwood Pharmaceuticals, Inc. ("Ironwood'), a commercial biotechnology company, focused on combining Ironwood's expertise in soluble guanylate cyclase (sGC) and Nicox's proprietary nitric oxide (NO)-donating research platform to generate novel compounds in order to identify potential new therapeutics for the treatment of certain ophthalmic conditions. Under the terms of the research collaboration agreement, each company will be responsible for their own costs associated with activities carried out as part of the collaboration. Depending on the outcome of the research collaboration, Nicox and Ironwood may then enter into discussions regarding Nicox's further development of any identified product candidate. Michael Bergamini, Ph.D., Executive Vice President, Chief Scientific Officer of Nicox, commented, "There is evidence to suggest that bringing together Ironwood and Nicox's respective expertise in sGC and NO-donating compounds can create new treatment options for ophthalmic conditions. We look forward to working with Ironwood on this exciting collaboration, with the goal of identifying potential new Nicox development pipeline candidates."

About Nicox Nicox S.A. is an international ophthalmic company, with two out-licensed commercial-stage products, developing innovative solutions to help maintain vision and improve ocular health. By leveraging its proprietary expertise in nitric oxide donation and other technologies, the Company is developing an extensive portfolio of novel drug candidates that target multiple ophthalmic conditions, including glaucoma. Nicox currently has two products with approved New Drug Applications, VYZULTA^TM (latanoprostene bunod ophthalmic solution) 0.024%, licensed worldwide to Bausch + Lomb, and ZERVIATE^TM (cetirizine ophthalmic solution) 0.24%, licensed in the U.S. to Eyevance. In addition, our promising drug-candidate pipeline includes clinical stage assets based both on our proprietary NO-donating research platform and on the repurposing of existing molecules as well as a next-generation of stand-alone nitric-oxide donors and exploratory novel NO-donating compounds with the potential to offer novel approaches to treat a range of ophthalmic conditions. Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. For more information on Nicox, its products or pipeline, please visit: www.nicox.com .

Analyst coverage
Bryan, Garnier & Co Hugo Solvet Paris, France Invest Securities Martial Descoutures Paris, France Gilbert Dupont Damien Choplain Paris, France
The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.
Upcoming financial and business conferences
June 4-7 2018 BIO International Convention Boston, USA June 27-28 European MidCap Event Paris, France October 1-3 Cantor Global Annual Healthcare Conference New York, USA November 22-23 Bryan Garnier 6^th Annual Healthcare Conference Paris, France
Contacts
Nicox Gavin Spencer, Executive Vice President Corporate Development T +33 (0)4 97 24 53 00 communications@nicox.com
Investor Relations Europe Nicox Corporate Communications Department T +33 (0)4 97 24 53 00 communications@nicox.com	Media Relations United Kingdom Jonathan Birt T +44 7860 361 746 jonathan.birt@ymail.com
United States Argot Partners Melissa Forst T +1 (212) 600-1902 melissa@argotpartners.com	France NewCap Nicolas Merigeau T +33 (0)1 44 71 94 98 nicox@newcap.eu
	United States Argot Partners David Rosen T +1 (212) 600-1902 david.rosen@argotpartners.com Italy Argon Healthcare International Pietro Pierangeli pietro.pierangeli@argonhealthcare.com Chiara Tettamanti chiara.tettamanti@argonhealthcare.com T. +39 02 4951.8300
Disclaimer
The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements. Risks factors which are likely to have a material effect on Nicox's business are presented in the 4th chapter of the ' Document de référence, rapport financier annuel et rapport de gestion 2016 ' filed with the French Autorité des Marchés Financiers (AMF) on March 29, 2017, and in the updated and additional risk factors as of August 14, 2017, which are available on Nicox's website ( www.nicox.com ).
Nicox S.A. Drakkar 2 Bât D, 2405 route des Dolines CS 10313, Sophia Antipolis 06560 Valbonne, France T +33 (0)4 97 24 53 00 F +33 (0)4 97 24 53 99

Attachment

Press release.pdf

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

UEG's New Advisory Board: Elevating Patient Voices

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Tomorrowland's Shanghai Return: An Electri-Lifesaver

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Antheia Secures $80M for Critical Medicine Onshoring

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

ASTS Faces a Legal Countdown – Investors Take Note

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Faith and Resilience in China: The Legacy of the Long March

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Lundbeck's Board Leadership Transitions into New Era

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

AEVEX Faces 48-Hour Deadline for Investor Class Action

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....